{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:27:22Z","timestamp":1770215242164,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,11,19]],"date-time":"2004-11-19T00:00:00Z","timestamp":1100822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2004,11,19]],"date-time":"2004-11-19T00:00:00Z","timestamp":1100822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Autoimmune Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Antibodies to a cytosolic soluble liver antigen (SLA) are specifically detected in patients with autoimmune hepatitis (AIH). The target of anti-SLA has been identified as a ~50 kDa UGA serine tRNA-associated protein complex (tRNP<jats:sup>(Ser)Sec<\/jats:sup>), through the screening of cDNA libraries. A recent report questioned the identity of tRNP<jats:sup>(Ser)Sec<\/jats:sup> as the real SLA antigen. The latter study identified \u03b1-enolase as a major anti-SLA target, through proteomic analysis.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>In an attempt to explain the observed discrepancy we have investigated reactivity of SLA positive sera against \u03b1-enolase and tRNP<jats:sup>(Ser)Sec<\/jats:sup> using rat and primate liver homogenate and the recombinant antigens. Thirty-three serum samples, 11 from SLA-positive patients and 22 from SLA negative controls were investigated. SLA antibodies were detected by an inhibition ELISA and confirmed by immunoblot using human liver homogenate. Autoantibody reactivity was further evaluated using preparations of primate and rat liver homogenates. Anti-\u03b1-enolase antibody reactivity has been tested by immunoblot using recombinant \u03b1-enolase. An affinity purified goat polyclonal anti-\u03b1-enolase IgG antibody was used as reference serum sample. Anti-tRNP<jats:sup>(Ser)Sec<\/jats:sup> antibody reactivity was detected by ELISA or dot blot using recombinant tRNP<jats:sup>(Ser)Sec<\/jats:sup> antigen.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results and Discussion<\/jats:title>\n                        <jats:p>The affinity purified IgG antibody directed to human \u03b1-enolase gave a band of approximately 48 kDa in both human and rat liver homogenates. A high titre anti-tRNP<jats:sup>(Ser)Sec<\/jats:sup> antibody serum gave a single band of ~50 kDa in both liver preparations. All but one anti-SLA antibody positive sera reacted with a ~50 kDa but none immunofixed a 48 kDa band. All anti-SLA antibody positive sera reacted strongly with the recombinant full length tRNP<jats:sup>(Ser)Sec<\/jats:sup> protein. None of the anti-SLA negative sera reacted with tRNP<jats:sup>(Ser)Sec<\/jats:sup>. Anti-SLA positive, and anti-SLA negative sera reacted equally against recombinant \u03b1-enolase by immunoblot. Pre-incubation of anti-SLA positive sera with tRNP<jats:sup>(Ser)Sec<\/jats:sup> completely abolished the 50 kDa band. The findings of the present study indicate that \u03b1-enolase and tRNP<jats:sup>(Ser)Sec<\/jats:sup> are both expressed in primate and rat liver and have a respective MW of 48 and 50 kDa. They also show that anti-tRNP<jats:sup>(Ser)Sec<\/jats:sup> \u2013 but not anti-\u03b1-enolase \u2013 correlates with anti-SLA antibody reactivity.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Our findings indicate that tRNP<jats:sup>(Ser)Sec<\/jats:sup> is the most likely target of anti-SLA.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1740-2557-1-4","type":"journal-article","created":{"date-parts":[[2005,1,12]],"date-time":"2005-01-12T13:55:34Z","timestamp":1105538134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antibodies to soluble liver antigen and \u03b1-enolase in patients with autoimmune hepatitis"],"prefix":"10.1186","volume":"1","author":[{"given":"Dimitrios-Petrou","family":"Bogdanos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragai R","family":"Mitry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Mieli-Vergani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Vergani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,11,19]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0140-6736(87)92024-1","volume":"1","author":"M Manns","year":"1987","unstructured":"Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH: Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987, 1: 292-294. 10.1016\/S0140-6736(87)92024-1.","journal-title":"Lancet"},{"key":"3_CR2","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/S0140-6736(00)02166-8","volume":"355","author":"I Wies","year":"2000","unstructured":"Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, Lohse AW: Identification of target antigen for SLA\/LP autoantibodies in autoimmune hepatitis. Lancet. 2000, 355: 1510-1515. 10.1016\/S0140-6736(00)02166-8.","journal-title":"Lancet"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1046\/j.1365-2249.2000.01280.x","volume":"121","author":"M Costa","year":"2000","unstructured":"Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C: Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol. 2000, 121: 364-374. 10.1046\/j.1365-2249.2000.01280.x.","journal-title":"Clin Exp Immunol"},{"key":"3_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/1566524013363672","volume":"1","author":"L Wen","year":"2001","unstructured":"Wen L, Ma Y, Bogdanos DP, Wong FS, Demaine A, Mieli-Vergani G, Vergani D: Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med. 2001, 1: 379-389.","journal-title":"Curr Mol Med"},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/jhep.2001.22218","volume":"33","author":"M Volkmann","year":"2001","unstructured":"Volkmann M, Martin L, Baurle A, Heid H, Strassburg CP, Trautwein C, Fiehn W, Manns MP: Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology. 2001, 33: 591-596. 10.1053\/jhep.2001.22218.","journal-title":"Hepatology"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/jhep.2002.32092","volume":"35","author":"Y Ma","year":"2002","unstructured":"Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Durr R, Mieli-Vergani G, Vergani D: Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002, 35: 658-664. 10.1053\/jhep.2002.32092.","journal-title":"Hepatology"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/0891693021000056712","volume":"35","author":"S Vitozzi","year":"2002","unstructured":"Vitozzi S, Djilali-Saiah I, Lapierre P, Alvarez F: Anti-soluble liver antigen\/liver-pancreas (SLA\/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity. 2002, 35: 485-492. 10.1080\/0891693021000056712.","journal-title":"Autoimmunity"},{"key":"3_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/0891693021000054101","volume":"35","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Shums Z, Norman GL: Frequency and significance of antibodies to soluble liver antigen\/liver pancreas in variant autoimmune hepatitis. Autoimmunity. 2002, 35: 475-483. 10.1080\/0891693021000054101.","journal-title":"Autoimmunity"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/gut.51.2.259","volume":"51","author":"M Baeres","year":"2002","unstructured":"Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, Porta G, Nishioka M, Simon T, Daehnrich C, Schlumberger W, Galle PR, Lohse AW: Establishment of standardised SLA\/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002, 51: 259-264. 10.1136\/gut.51.2.259.","journal-title":"Gut"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1089-3261(02)00018-1","volume":"6","author":"D Vergani","year":"2002","unstructured":"Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G: Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002, 6: 439-449.","journal-title":"Clin Liver Dis"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1373\/49.4.634","volume":"49","author":"E Ballot","year":"2003","unstructured":"Ballot E, Bruneel A, Labas V, Johanet C: Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis. Clin Chem. 2003, 49: 634-643. 10.1373\/49.4.634.","journal-title":"Clin Chem"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1006\/jaut.1998.0239","volume":"11","author":"G Adamus","year":"1998","unstructured":"Adamus G, Amundson D, Seigel GM, Machnicki M: Anti-enolase-alpha autoantibodies in cancer-associated retinopathy: epitope mapping and cytotoxicity on retinal cells. J Autoimmun. 1998, 11: 671-677. 10.1006\/jaut.1998.0239.","journal-title":"J Autoimmun"},{"key":"3_CR13","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/art.11074","volume":"48","author":"KH Lee","year":"2003","unstructured":"Lee KH, Chung HS, Kim HS, Oh SH, Ha MK, Baik JH, Lee S, Bang D: Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behcet's disease. Arthritis Rheum. 2003, 48: 2025-2035. 10.1002\/art.11074.","journal-title":"Arthritis Rheum"},{"key":"3_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/ki.1993.97","volume":"43","author":"FD Moodie","year":"1993","unstructured":"Moodie FD, Leaker B, Cambridge G, Totty NF, Segal AW: Alpha-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis. Kidney Int. 1993, 43: 675-681.","journal-title":"Kidney Int"},{"key":"3_CR15","first-page":"109","volume":"27","author":"F Pratesi","year":"2000","unstructured":"Pratesi F, Moscato S, Sabbatini A, Chimenti D, Bombardieri S, Migliorini P: Autoantibodies specific for alpha-enolase in systemic autoimmune disorders. J Rheumatol. 2000, 27: 109-115.","journal-title":"J Rheumatol"},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1046\/j.1365-2249.1998.00528.x","volume":"112","author":"C Roozendaal","year":"1998","unstructured":"Roozendaal C, Zhao MH, Horst G, Lockwood CM, Kleibeuker JH, Limburg PC, Nelis GF, Kallenberg CG: Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD). Clin Exp Immunol. 1998, 112: 10-16. 10.1046\/j.1365-2249.1998.00528.x.","journal-title":"Clin Exp Immunol"},{"key":"3_CR17","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/art.10252","volume":"46","author":"V Saulot","year":"2002","unstructured":"Saulot V, Vittecoq O, Charlionet R, Fardellone P, Lange C, Marvin L, Machour N, Le Loet X, Gilbert D, Tron F: Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum. 2002, 46: 1196-1201. 10.1002\/art.10252.","journal-title":"Arthritis Rheum"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1507\/endocrj.50.697","volume":"50","author":"S Tanaka","year":"2003","unstructured":"Tanaka S, Tatsumi KI, Takano T, Murakami Y, Takao T, Yamakita N, Tahara S, Teramoto A, Hashimoto K, Kato Y, Amino N: Anti-alpha-enolase antibodies in pituitary disease. Endocr J. 2003, 50: 697-702. 10.1507\/endocrj.50.697.","journal-title":"Endocr J"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1373\/clinchem.2003.027730","volume":"50","author":"DP Bogdanos","year":"2004","unstructured":"Bogdanos DP, Bianchi I, Ma Y, Mitry RR, Mieli-Vergani G, Vergani D: Targets of antibodies to soluble liver antigen in patients with autoimmune hepatitis. Clin Chem. 2004, 50: 682-3; author reply 683-4. 10.1373\/clinchem.2003.027730.","journal-title":"Clin Chem"},{"key":"3_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaut.2004.03.002","volume":"22","author":"DP Bogdanos","year":"2004","unstructured":"Bogdanos DP, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, Burroughs AK, Rodes J, Vergani D: Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun. 2004, 22: 353-362. 10.1016\/j.jaut.2004.03.002.","journal-title":"J Autoimmun"}],"container-title":["Journal of Autoimmune Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1740-2557-1-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1740-2557-1-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1740-2557-1-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:32:54Z","timestamp":1728304374000},"score":1,"resource":{"primary":{"URL":"https:\/\/jautoimdis.biomedcentral.com\/articles\/10.1186\/1740-2557-1-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,19]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,12]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1186\/1740-2557-1-4","relation":{},"ISSN":["1740-2557"],"issn-type":[{"value":"1740-2557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,19]]},"assertion":[{"value":"8 October 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"4"}}